Search Result

Isoforms Recommended:	MT2

Results for "

MT-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (11) Antibiotic (1) Apoptosis (1) Drug Metabolite (2) Endogenous Metabolite (6) HIV (4) HIV Integrase (2) HIV Protease (1) Isotope-Labeled Compounds (4) Melatonin Receptor (30) P2X Receptor (1) Parasite (1) Reverse Transcriptase (1) Small Interfering RNA (siRNA) (1) Sodium Channel (1) TRP Channel (1)
By Research Areas:	Cancer (6) Endocrinology (9) Infection (8) Inflammation/Immunology (1) Metabolic Disease (1) Neurological Disease (28)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101358

8-M-PDOT AH-002	Melatonin Receptor	Neurological Disease
8-M-PDOT (AH-002) is a selective *melatonin MT2* receptor agonist. 8-M-PDOT is 5.2-fold selective for MT2 over MT1 receptors. 8-M-PDOT binds human recombinant MT2** and MT2 receptors with pKi values of 8.23 and 8.95 respectively. 8-M-PDOT has anxiolytic-like activity ^[2].

HY-122136

S26131 5+ Cited Publications	Melatonin Receptor	Neurological Disease
S26131 (compound 5) is a potent and selective MT1 melatoninergic ligand, and the K_i values are 0.5 and 112 nM for MT1 and MT2, respectively. S26131 behaves as an MT1 and MT2 antagonist .

HY-101254

Luzindole Maximum Cited Publications 12 Publications Verification N-0774	Melatonin Receptor	Neurological Disease
Luzindole (N-0774) is a selective melatonin receptor antagonist. Luzindole preferentially targets MT2 (Mel_1b) over MT1 (Mel_1a) with K_i values of 10.2 and 158 nM for human MT2 and MT1, respectively. Luzindole suppresses experimental autoimmune encephalomyelitis (EAE), and exerts antidepressant-like activity ^[2] .

HY-17038S

Agomelatine-d6 S-20098-d₆	Isotope-Labeled Compounds Melatonin Receptor 5-HT Receptor	Neurological Disease
Agomelatine-d₆ is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors[1] .

HY-101074

UCM 608 2-Phenylmelatonin	Melatonin Receptor	Neurological Disease Inflammation/Immunology Cancer
UCM 608 is a high affinity melatonin (MT) membrane receptor agonist. The pKi values for MT1 and *MT2* are 10.7 and 10.4 ^[2].

HY-RS08743

MT2A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
MT2A Human Pre-designed siRNA Set A contains three designed siRNAs for MT2A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MT2A Human Pre-designed siRNA Set A MT2A Human Pre-designed siRNA Set A

HY-107628

DH97	Melatonin Receptor	Neurological Disease
DH97 is a potent and selective antagonist of MT₂ melatonin receptor, with a pK_i of 8.03 for human MT₂. DH97 shows 89- and 229-fold selectivity for human MT₂ over human mt₁ and Xenopus mel_1c receptor subtypes. DH97 can inhibit melatonin-induced enhancement of electrically-evoked responses ^[2].

HY-119010

UCM 549	Melatonin Receptor	Neurological Disease
UCM 549 is a *melatonin MT2* receptor inverse agonist and a MT1 receptor** antagonist .

HY-150079

HIV-1 integrase inhibitor 10	HIV Integrase	Infection
HIV-1 integrase inhibitor 10 is an orally active HIV-1 allosteric integrase inhibitor (ALLINI). HIV-1 integrase inhibitor 10 can inhibit viral outgrowth of the NLRepRluc virus in MT-2 cells with EC₅₀ values of 3-5 nM. HIV-1 integrase inhibitor 10 can be used for the research of Human immunodeficiency virus-1 (HIV-1) .

HY-147542

Melatonin receptor agonist 1	Melatonin Receptor	Neurological Disease
Melatonin receptor agonist 1 (compound 20c) is a potent melatonin receptor (MT) agonist, with K_i values of 108 nM (MT₂) and 1140 nM (MT₁) .

HY-100609

4-P-PDOT 5 Publications Verification	Melatonin Receptor	Neurological Disease
4-P-PDOT is a potent, selective and affinity Melatonin receptor (MT2) antagonist. 4-P-PDOT is >300-fold more selective for *MT2* than MT1. 4-P-PDOT significantly counteracts Melatonin-mediated antioxidant effects (GSH/GSSG ratio, phospho-ERK, Nrf2 nuclear translocation, Nrf2 DNA-binding activity) ^[2] .

HY-138626

ACH-000143	Melatonin Receptor	Metabolic Disease
ACH-000143 is a potent and orally active melatonin receptor agonist, with EC₅₀ values of 0.06 nM and 0.32 nM for MT1 and MT2, respectively .

HY-103005

Ramelteon metabolite M-II	Melatonin Receptor Drug Metabolite	Neurological Disease Endocrinology
Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC₅₀s of 208 pM, 1470 pM for human melatonin receptors (MT₁ or MT₂). Ramelteon is a selective melatonin agonist.

HY-133113

7-Desmethyl-agomelatine 1 Publications Verification	5-HT Receptor	Neurological Disease
7-Desmethyl-agomelatine is a metabolite of Agomelatine. Agomelatineis a potent agonist at melatonin receptors (MT1 and MT2), and also is an antagonist of 5-HT2C ^[2].

HY-A0014

Ramelteon 5+ Cited Publications TAK-375	Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon is a potent, highly selective, and orally active agonist of *MT1/MT2* with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation ^[2].

HY-B0439S1

Sulfadoxine D3 Sulphadoxine d₃	Parasite Antibiotic	Infection
Sulfadoxine-d₃ is a deuterium labeled Sulfadoxine (HY-B0439). Sulfadoxine is a sulfonamide that is used, usually in combination with Pyrimethamine (HY-18062), for multidrug-resistant Plasmodium falciparum and P. vivax inhibition. Unlike PYR, Sulfadoxine has no impact on HIV replication or MT-2 cell cycle progression. But also Sulfadoxine exhibits suppression on respiratory, and urinary tract infections[1][2][3][4].

HY-A0014S

Ramelteon-d5 TAK-375-d₅	Isotope-Labeled Compounds Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].

HY-A0014R

Ramelteon (Standard)	Melatonin Receptor	Neurological Disease Endocrinology Cancer
Ramelteon (Standard) is the analytical standard of Ramelteon. This product is intended for research and analytical applications. Ramelteon is a potent, highly selective, and orally active agonist of *MT1/MT2* with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation ^[2].

HY-133112

7-Desmethyl-3-hydroxyagomelatine 3-Hydroxy-7-desmethyl agomelatine	Melatonin Receptor 5-HT Receptor	Neurological Disease
7-Desmethyl-3-hydroxyagomelatine (3-Hydroxy-7-desmethyl agomelatine), a metabolite of Agomelatine, has less activity than Agomelatine . Agomelatine is a melatonergic (MT1 and *MT2) agonist and serotonergic* (5HT2C) antagonist ^[2].

HY-101176

2-Iodomelatonin 2 Publications Verification	Melatonin Receptor	Cancer
2-Iodomelatonin is a potent agonist of melatonin receptor 1 (MT1) with a K_i value of 28 pM, it is more 5-fold selective for MT₁ over MT₂ . 2-iodomelatonin can be used to identify, characterize and localize melatonin binding sites in the brain and peripheral tissues .

HY-103005S

Ramelteon metabolite M-II-d3	Melatonin Receptor Drug Metabolite	Neurological Disease Endocrinology
Ramelteon metabolite M-II-d₃ is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist[1][2].

HY-14803

Tasimelteon BMS-214778; VEC-162	Melatonin Receptor	Neurological Disease Endocrinology
Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24) ^[2].

HY-105285

Piromelatine Neu-P11	Melatonin Receptor 5-HT Receptor P2X Receptor TRP Channel Sodium Channel	Neurological Disease
Piromelatine (Neu-P11) is a melatonin MT₁/MT₂ receptor agonist, serotonin 5-HT_1A/5-HT_1D agonist, and serotonin 5-HT_2B antagonist. Piromelatine (Neu-P11) possesses sleep promoting, analgesic, anti-neurodegenerative, anxiolytic and antidepressant potentials. Piromelatine (Neu-P11) also possesses pain-related P2X3, TRPV1, and Nav1.7 channel-inhibition capacities ^[2] .

HY-14803S

Tasimelteon-d5 BMS-214778-d₅; VEC-162-d₅	Isotope-Labeled Compounds Melatonin Receptor	Neurological Disease Endocrinology
Tasimelteon-d₅ is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].

HY-100940

6-Chloromelatonin	Melatonin Receptor	Endocrinology
6-Chloromelatonin is a potent melatonin receptor agonist with greater metabolic stability than melatonin. 6-Chloromelatonin compete for [ ³H]-melatonin and 2-[ ¹²⁵I]-iodomelatonin binding to MT1 receptors (pK_i=8.9 and 9.1, respectively). 6-Chloromelatonin compete for [ ³H]-melatonin binding to MT2 receptors (pK_i=9.77) ^[2].

HY-14803R

Tasimelteon (Standard)	Melatonin Receptor	Neurological Disease Endocrinology
Tasimelteon (Standard) is the analytical standard of Tasimelteon. This product is intended for research and analytical applications. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24) ^[2].

HY-114962

S-22153	Melatonin Receptor	Neurological Disease
S-22153 is a potent melatonin receptor antagonist with EC₅₀ values of 19 nM, 4.6 nM for hMT₁ and *hMT₂* melatonin receptor, respectively. S-22153 has K_i values of 8.6 nM (CHO cells) and 16.3 nM (HEK cells) for hMT₁, and 6.0 nM (CHO cells) and 8.2 nM (HEK cells) for hMT₂. S-22153 is a specific ligand of MT₁ and MT₂ melatonin receptors subtypes ^[2].

HY-106136

TIK-301 PD-6735; LY-156735	Melatonin Receptor 5-HT Receptor	Neurological Disease
TIK-301 (PD-6735) is a chlorinated melatonin derivative and a potent, high-affinity and orally active melatonin MT₁ and MT₂ receptors agonist with K_is of 0.081 nM and 0.042 nM, respectively. TIK-301 is also a 5-HT_2B/5-HT_2C receptors antagonist with antidepressant action. TIK-301 has the potential for sleep disorders and other circadian rhythm disorders treatment ^[2] .

HY-17038

Agomelatine 3 Publications Verification S-20098	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

HY-17038A

Agomelatine hydrochloride 3 Publications Verification S-20098 hydrochloride	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

HY-17038B

Agomelatine (L(+)-Tartaric acid) 3 Publications Verification S-20098 L(+)-Tartaric acid	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

HY-17038R

Agomelatine (Standard)	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine (Standard) is the analytical standard of Agomelatine. This product is intended for research and analytical applications. Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

HY-17038S1

Agomelatine-d4 S-20098-d₄	Isotope-Labeled Compounds Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatine-d₄ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-17038S2

Agomelatin-d3 S-20098-d₃	Melatonin Receptor 5-HT Receptor Endogenous Metabolite	Neurological Disease
Agomelatin-d₃ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-139090

3-Oxobetulin acetate 28-O-Acetyl-3-Oxobetulin; 3-oxo-28-O-Acetylbetulin	Others	Infection
3-Oxobetulin acetate is a derivative of the cholesterol biosynthesis inhibitor Betulin (HY-N0083). It inhibits the growth of P388 murine lymphocytic leukemia cells (EC₅₀=0.12 μg/mL), as well as human MCF-7 breast, SF-268 CNS, H460 lung, and KM20L2 colon cancer cells (GI₅₀s=8, 10.6, 5.2, and 12.7 μg/mL, respectively), but not BxPC-3 pancreas or DU145 prostate cancer cells (GI₅₀s=>10 μg/mL for both).2 3-Oxobetulin acetate inhibits replication of X4 tropic recombinant HIV (NL4.3-Ren) in MT-2 lymphoblastoid cells (IC₅₀=13.4 μM). It is also active against L. donovani amastigotes when used at a concentration of 50 μM.

HY-153782

GSK878	HIV	Infection
GSK878 is a highly potent, long-acting HIV-1 inhibitor with the EC₅₀ of 39 pM .

HY-162525

GS-9770	HIV Protease	Infection
GS-9770 is an orally active inhibitor for HIV protease with K_i of 0.16 nM. GS-9770 exhibits antiviral activity aginst HIV-1 strains and HIV-2 strains with EC₅₀ of 1.9-26 nM, and 26 nM. GS-9770 is metabolic stable in human liver microsomes. GS-9770 exhibits good pharmacokinetic characters in Sprague Dawley rats .

HY-122018

GS-9148	HIV Reverse Transcriptase	Infection
GS-9148 is a ribose-modified HIV-1 nucleotide reverse transcriptase (RT) inhibitor with an EC₅₀ value of 10.6 µM. GS-9148 shows antiretroviral activity for K65R, L74V, or M184V RT mutation .

HY-139985

NBD-14189	HIV	Infection
NBD-14189 is a potent HIV-1 entry antagonist with an IC₅₀ of 89 nM against the HIV-1_HXB2 pseudovirus. NBD-14189 binds to HIV-1 gp120 and shows potent antiviral activity (EC₅₀<200 nM) ^[2].

HY-17605A

Bictegravir sodium 5+ Cited Publications GS-9883 sodium	HIV Integrase HIV	Infection
Bictegravir sodium is a potent inhibitor of HIV-1 integrase, with an IC₅₀ of 7.5 nM. Bictegravir sodium exhibits potent and selective anti-HIV activity and low cytotoxicity .

HY-120075

TJ191	Apoptosis	Cancer
TJ191 is a potent and specific anti-cancer agent that targets low TβRIII-expressing malignant T-cell leukemia/lymphoma cells. TJ191 has no affects on the proliferation of other cancer cells or normal fibroblasts or immune cells. TJ191 can be used for cancer research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-17038

Agomelatine 3 Publications Verification S-20098	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

HY-17038A

Agomelatine hydrochloride 3 Publications Verification S-20098 hydrochloride	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

HY-17038B

Agomelatine (L(+)-Tartaric acid) 3 Publications Verification S-20098 L(+)-Tartaric acid	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine L(+)-Tartaric acid is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

HY-17038R

Agomelatine (Standard)	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (Standard) is the analytical standard of Agomelatine. This product is intended for research and analytical applications. Agomelatine (S-20098) is a specific agonist of MT1 and *MT2* receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective 5-HT2C receptor antagonist with pK_is of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively ^[2].

Cat. No.	Product Name	Chemical Structure

HY-17038S

Agomelatine-d6
Agomelatine-d₆ is deuterium labeled Agomelatine. Agomelatine is a specific agonist of MT1 and MT2 receptors[1] .

HY-B0439S1

Sulfadoxine D3

Sulfadoxine-d₃ is a deuterium labeled Sulfadoxine (HY-B0439). Sulfadoxine is a sulfonamide that is used, usually in combination with Pyrimethamine (HY-18062), for multidrug-resistant Plasmodium falciparum and P. vivax inhibition. Unlike PYR, Sulfadoxine has no impact on HIV replication or MT-2 cell cycle progression. But also Sulfadoxine exhibits suppression on respiratory, and urinary tract infections[1][2][3][4].

HY-103005S

Ramelteon metabolite M-II-d3
Ramelteon metabolite M-II-d₃ is the deuterium labeled Ramelteon metabolite M-II. Ramelteon metabolite M-II is the major metabolite of Ramelteon, with IC50s of 208 pM, 1470 pM for human melatonin receptors (MT1 or MT2). Ramelteon is a selective melatonin agonist[1][2].

HY-17038S2

Agomelatin-d3
Agomelatin-d₃ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-A0014S

Ramelteon-d5

Ramelteon-d₅ is deuterium labeled Ramelteon. Ramelteon is a potent, highly selective, and orally active agonist of MT1/MT2 with Ki values of 14 and 112 pM, respectively. Ramelteon has the potential for the research of insomnia. Ramelteon consistently reduces sleep onset after long-term treatment, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation[1][2].

HY-14803S

Tasimelteon-d5
Tasimelteon-d₅ is the deuterium labeled Tasimelteon. Tasimelteon (BMS-214778) is an orally active and selective dual melatonin receptor agonist (DMRA). Tasimelteon has 2.1-4.4 times greater affinity for the MT2 receptor than for the MT1 receptor. Tasimelteon is a circadian regulator and has the potential for Non-24-Hour Sleep-Wake Disorder (Non-24)[1][2].

HY-17038S1

Agomelatine-d4
Agomelatine-d₄ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks